C. R. Bard Inc. has entered into a definitive merger agreement to acquire Rochester Medical Corp. at a price of $20 per share, or approximately $262 million in the aggregate. The Rochester Medical board of directors unanimously approved the agreement and will recommend that the company's shareholders approve the transaction.

 
 

Based on its recent analysis of the cardiology informatics market, Frost & Sullivan recognizes Ascend HiT with the 2013 North America Frost & Sullivan Award for Customer Value Leadership. With the introduction of CardioAnalytics, Ascend has proved that it is at the vanguard of the cardiology market's efforts to enhance quality and analytics. This product complements and extends the best-of-breed Ascend CV reporting products, and in the process, positions the company to deliver one of the most crucial elements of the cardiology value chain—cardiovascular procedural reporting.


September 3, 2013 — St. Jude Medical Inc. announced the CE mark approval of its next-generation EnligHTN renal denervation system for treating patients with drug-resistant, uncontrolled hypertension. The EnligHTN system was display during the 2013 European Society of Cardiology (ESC) meeting Aug. 31 to Sept. 3.

St. Jude Medical Inc. today announced U.S. Food and Drug Administration (FDA) approval and first use of MediGuide Enable Ablation Catheters. The ablation catheters, which are used to treat specific irregular heartbeats, expand the MediGuide platform for St. Jude Medical.

Avinger Inc. has received CE Mark approval for Pantheris – a system that combines directional atherectomy capabilities with real-time intravascular visualization to remove plaque from blocked arteries. Pantheris is designed to remove the blockage while avoiding the disruption of normal arterial wall structures. This new type of image-guided atherectomy is referred to as lumectomy. Currently, approximately 200 million patients worldwide suffer from peripheral artery disease (PAD).

 

Ascendian Healthcare Consulting has announced a comprehensive vendor neutral archive (VNA) acceleration solution that enables healthcare organizations rapid accessibility, efficiency and shared utilization of medical imaging assets. 

August 30, 2013 — PFM Medical received U.S. Food and Drug Administration (FDA) premarket approval (PMA) for its Nit-Occlud Patent Ductus Arteriosus (PDA) device, a permanently implanted prosthesis indicated for percutaneous, transcatheter closure of small to moderate size patent ductus arteriosus.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now